Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00220194
Status:
COMPLETED
Last Update Posted:
2016-10-14
First Post:
2005-09-17
Brief Title:
A Six-Month Open-Label Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 225 Mg And Eligard 225 Mg Or Zoladex 108 Mg And Eligard 225 Mg In Patients With Advanced Prostate Cancer
Sponsor:
Organization:
San Bernardino Urological Associates Medical Group Inc
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
100
Enrollment Type:
None
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE4 |
Observational Models:
Time Perspective List:
Who Masked List: